Ena 713 Free Base
Ena 713 Free Base Brand names, Ena 713 Free Base Analogs
Ena 713 Free Base Brand Names Mixture
- No information avaliable
Ena 713 Free Base Chemical_Formula
C14H22N2O2
Ena 713 Free Base RX_link
http://www.rxlist.com/cgi/generic2/rivastig.htm
Ena 713 Free Base fda sheet
Ena 713 Free Base msds (material safety sheet)
Ena 713 Free Base Synthesis Reference
No information avaliable
Ena 713 Free Base Molecular Weight
250.337 g/mol
Ena 713 Free Base Melting Point
No information avaliable
Ena 713 Free Base H2O Solubility
No information avaliable
Ena 713 Free Base State
Solid
Ena 713 Free Base LogP
2.611
Ena 713 Free Base Dosage Forms
Capsule; Solution
Ena 713 Free Base Indication
For the treatment of mild to moderate Alzheimer's disease.
Ena 713 Free Base Pharmacology
Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. Rivastigmine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Pathological changes in Dementia of the Alzheimer type involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways are thought to be intricately involved in memory, attention, learning, and other cognitive processes. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact.
Ena 713 Free Base Absorption
No information avaliable
Ena 713 Free Base side effects and Toxicity
No information avaliable
Ena 713 Free Base Patient Information
Caregivers should be advised of the high incidence of nausea and vomiting associated with the use of the drug along with the possibility of anorexia and weight loss. Caregivers should be encouraged to monitor for these adverse events and inform the physician if they occur. It is critical to inform caregivers that if therapy has been interrupted for more than several days, the next dose should not be administered until they have discussed this with the physician.
Ena 713 Free Base Organisms Affected
Humans and other mammals
